Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET)
CUSIP: 007002108
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 9,599,852
- Total 13F shares
- 57,616,208
- Share change
- -553,061
- Total reported value
- $55,430,722
- Put/Call ratio
- 538%
- Price per share
- $0.96
- Number of holders
- 61
- Value change
- -$613,083
- Number of buys
- 18
- Number of sells
- 29
Quarterly Holders Quick Answers
What is CUSIP 007002108?
CUSIP 007002108 identifies ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 007002108:
Top shareholders of ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
119%
|
11,447,140
|
$16,483,882 | — | 30 Sep 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
86%
|
8,216,960
|
$11,832,422 | — | 30 Sep 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
79%
|
7,541,000
|
$10,859,040 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
39%
|
3,759,997
|
$5,414,396 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
33%
|
3,205,882
|
$4,616,470 | — | 30 Sep 2024 | |
| Carlyle Group Inc. |
13F
|
Company |
31%
|
2,948,718
|
$4,246,154 | — | 30 Sep 2024 | |
| Aquilo Capital Management, LLC |
13F
|
Company |
26%
|
2,531,194
|
$3,644,919 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
20%
|
1,958,727
|
$2,820,567 | — | 30 Sep 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
20%
|
1,879,933
|
$2,706,000 | — | 30 Sep 2024 | |
| Blackstone Inc. |
13F
|
Company |
13%
|
1,236,453
|
$1,780,492 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
13%
|
1,231,600
|
$1,773,504 | — | 30 Sep 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
9.6%
|
917,070
|
$1,320,580 | — | 30 Sep 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.9%
|
851,600
|
$1,226,304 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8%
|
768,566
|
$1,107,004 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
7.8%
|
752,009
|
$1,082,894 | — | 30 Sep 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
7.4%
|
706,639
|
$1,017,560 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
7.3%
|
703,419
|
$1,012,923 | — | 30 Sep 2024 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
6.8%
|
655,665
|
$944,158 | — | 30 Sep 2024 | |
| Carl L. Gordon |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
684,857
mixed-class rows
|
$941,594 | — | 21 Aug 2024 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
6.3%
|
609,446
|
$877,602 | — | 30 Sep 2024 | |
| RBF Capital, LLC |
13F
|
Company |
6.3%
|
601,135
|
$865,634 | — | 30 Sep 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
6.3%
|
600,000
|
$864,000 | — | 30 Sep 2024 | |
| NORGES BANK |
13F
|
Company |
4.5%
|
429,550
|
$618,552 | — | 30 Sep 2024 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.8%
|
364,472
|
$524,840 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
3.8%
|
364,342
|
$524,652 | — | 30 Sep 2024 | |
| XTX Topco Ltd |
13F
|
Company |
3%
|
292,180
|
$420,739 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
2.9%
|
276,169
|
$397,683 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.8%
|
268,909
|
$387,229 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.4%
|
229,721
|
$330,798 | — | 30 Sep 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.9%
|
180,793
|
$260,342 | — | 30 Sep 2024 | |
| Francesco Galimi |
3/4/5
|
SVP & Chief Medical Officer |
—
mixed-class rows
|
476,878
mixed-class rows
|
$244,322 | — | 05 Jun 2024 | |
| Aya Jakobovits |
3/4/5
|
Director |
—
mixed-class rows
|
176,276
mixed-class rows
|
$214,323 | — | 21 Aug 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.5%
|
147,814
|
$212,832 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.5%
|
145,200
|
$209,088 | — | 30 Sep 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.4%
|
130,950
|
$188,568 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.2%
|
112,216
|
$161,591 | — | 30 Sep 2024 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
1.2%
|
111,642
|
$160,764 | — | 30 Sep 2024 | |
| Diametric Capital, LP |
13F
|
Company |
1.1%
|
109,783
|
$158,087 | — | 30 Sep 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.94%
|
89,872
|
$129,416 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.84%
|
80,353
|
$115,708 | — | 30 Sep 2024 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.82%
|
78,704
|
$112,547 | — | 30 Sep 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.78%
|
74,767
|
$107,664 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.73%
|
70,232
|
$101,135 | — | 30 Sep 2024 | |
| Castleview Partners, LLC |
13F
|
Company |
0.55%
|
52,368
|
$75,410 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.45%
|
43,110
|
$62,078 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.43%
|
41,604
|
$59,910 | — | 30 Sep 2024 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.43%
|
41,115
|
$59,206 | — | 30 Sep 2024 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.42%
|
40,000
|
$57,600 | — | 30 Sep 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.42%
|
39,980
|
$57,571 | — | 30 Sep 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.41%
|
39,208
|
$56,000 | — | 30 Sep 2024 |
Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) as of Q4 2024
As of 31 Dec 2024,
Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,616,208 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, TANG CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, Carlyle Group Inc., Aquilo Capital Management, LLC, ACADIAN ASSET MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, and Blackstone Inc..
This page lists
62
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
62
Q4 2024 holders
61
Holder diff
-1
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.